Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2015

View Archived Issues

Phase Ib trial set to evaluate tolerogenic dendritic cells for MS and neuromyelitis optica

Encouraging results on S-44858 for the treatment of CNS diseases

Inotek Pharmaceuticals provides update on development strategy for trabodenoson

Chugai updates pipeline progress of second quarter 2015

DiffronC Technology targeting NR2F6 shows potential for the treatment of leukemia

PharmaMar forms license agreement with TTY Biopharm for Aplidin

CEA-Leti and Diabeloop to develop artificial pancreas to improve diabetes treatment

Novel GSM shows promise for the treatment of AD

Brincidofovir reduces mortality in animal model of smallpox

Cara Therapeutics reports data from phase II trial in uremic pruritus

Norgine patents CCR9 antagonists

Purdue Pharma discloses opioid receptor agonists

Merck & Co. develops ROMK channel blockers

Polyphor divulges selective elastase inhibitors

Lifesci Pharmaceuticals reports KLKB1 inhibitors

Model created to investigate the role of butyrylcholinesterase in Alzheimer's disease

Bristol-Myers Squibb describes IRAK-4 inhibitors

EMA accepts for review MAA for grazoprevir/elbasvir in HCV

Sunesis updates regulatory progress for vosaroxin in AML

EMA committee adopts positive scientific opinion for Mosquirix

Inovio and EORTC to conduct phase II trial of INO-3112 in cervical cancer

Janssen files sNDA for reduced-duration treatment with simeprevir in HCV infection

New preclinical study investigates PharmaCyte's treatment in ascites

Baxalta acquires asparaginase portfolio from Sigma-Tau

Amgen submits sNDA for Kyprolis in relapsed multiple myeloma

AstraZeneca forms partnership with inhaler monitoring company Adherium

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...